Omalizumab

Active substance
Omalizumab
Domain
Lung diseases
Reason of inclusion in Horizonscan Geneesmiddelen
Biosimilar
Main indication
Asthma
Extended indication
Aanvullende behandeling om de astmacontrole te verbeteren bij patiënten met ernstig persistent allergisch astma.

1. Product

Current proprietary name
Xolair (Novartis)
Proprietary name
STI-004
Manufacturer
Sorrento Therapeutics
Mechanism of action
Interleukin inhibitor

2. Registration

Registration route
Centralised (EMA)
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Fase II/III studie afgerond in mei 2016. SPC Xolair is verlopen.

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.